Restoring Biological Harmony for Patients with Debilitating Disease
We are harnessing the power of microRNA science to develop therapies that normalize biological pathways and counterbalance disease.
Learn More
DEVELOPMENT PROGRAMS
Our pipeline is focused on serious diseases of high unmet need where the latest discoveries in microRNA biology are challenging traditional drug development paradigms and creating opportunities for novel therapeutic approaches.
MIRAGEN CEO FEATURED IN BIZWEST
miRagen’s CEO Bill Marshall was interviewed by BizWest about his goal to address three disease categories: blood cancers, which include leukemias and lymphomas; pathologic fibrosis; and cardiovascular disease.
READ ARTICLE >
Recent Press Releases
- miRagen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
- miRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell Lymphoma
- miRagen Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
- miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018
- miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201